We thus performed a retrospective study aimed to determine whether HER2+ patients after BCS with primary T0–T2N0M0 breast cancer can benefit from RT based on data from the Surveillance, Epidemiology, and End Results (SEER) program. The gene discussed is ERBB2; the disease is breast cancer.